High affinity NY-ESO T cell receptors
View Patent ↗The present invention provides T cell receptors (TCRs) having the property of binding to SLLMWITQC-HLA-A*0201, the SLLMWITQC SEQ ID NO:126 peptide being derived from the NY-ESO-1 protein which is expressed by a range of tumor cells. The TCRs have a K D for the said peptide-HLA complex of less than or equal to 1 μM and/or have an off-rate (k off ) of 1×10 −3 S −1 or slower.
1. A recombinant TCR having the α chain extracellular sequence SEQ ID NO: 1 and the β chain extracellular sequence SEQ ID NO: 2 except that amino acids Q51 and S53 of SEQ ID NO: 1 are replaced by 51M and 53H and amino acid G50 of SEQ ID NO: 2 is replaced by 50S.
2. A pharmaceutical composition comprising: a plurality of cells having the TCR of claim 1 ; and a pharmaceutically acceptable carrier.
3. A recombinant TCR having the α chain extracellular sequence SEQ ID NO: 1 and the β chain extracellular sequence SEQ ID NO: 2 except that amino acids Q51 and S53 of SEQ ID NO: 1 are replaced by 51M and 53H and amino acid A51 of SEQ ID NO: 2 is replaced by 51V.
4. A pharmaceutical composition comprising: a plurality of cells having the TCR of claim 3 ; and a pharmaceutically acceptable carrier.
5. A recombinant TCR having the α chain extracellular sequence SEQ ID NO: 5 and the β chain extracellular sequence SEQ ID NO: 6 except that amino acids Q51 and S53 of SEQ ID NO: 5 are replaced by 51M and 53H and amino acid A51 of SEQ ID NO: 6 is replaced by 51V and amino acid T162 of the α chain and amino acid S169 of the 13 chain are replaced by 162C and 169C and comprising a disulfide bond between α chain 162C and β chain 169C, using the numbering of SEQ ID NOs: 5 and 6.
6. An isolated cell having a TCR having the α chain extracellular sequence SEQ ID NO: 1 and the β chain extracellular sequence SEQ ID NO: 2 except that amino acids Q51 and S53 of SEQ ID NO: 1 are replaced by 51M and 53H and amino acid G50 of SEQ ID NO: 2 is replaced by 50S.
7. An isolated cell having a TCR having the α chain extracellular sequence SEQ ID NO:5 and the β chain extracellular sequence SEQ ID NO: 6 except that amino acids Q51 and S53 of SEQ ID NO: 5 are replaced by 51M and 53H and amino acid G50 of SEQ ID NO: 6 is replaced by 50S and amino acid T162 of the α chain and amino acid S169 of the β chain are replaced by 162C and 169C and comprising a disulfide bond between α chain 162C and β chain 169C, using the numbering of SEQ ID NOs: 5 and 6.
8. An isolated cell having a TCR having the α chain extracellular sequence SEQ ID NO: 1 and the β chain extracellular sequence SEQ ID NO: 2 except that amino acids Q51 and S53 of SEQ ID NO: 1 are replaced by 51M and 53H and amino acid A51 of SEQ ID NO: 2 is replaced by 51V.
9. An isolated cell having a TCR having the α chain extracellular sequence SEQ ID NO: 5 and the chain extracellular sequence SEQ ID NO: 6 except that amino acids Q51 and S53 of SEQ ID NO: 5 are replaced by 51M and 53H and amino acid A51 of SEQ ID NO: 6 is replaced by 51V and amino acid T162 of the α chain and amino acid S169 of the β chain are replaced by 162C and 169C and comprising a disulfide bond between α chain 162C and β chain 169C, using the numbering of SEQ ID NOs: 5 and 6.